| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.059 | 0.3 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.3 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.054 | 0.3 |